The management of PSA failure after radical radiotherapy for localized prostate cancer

Radiotherapy and Oncology

Volumn 49, Issue 2, 1998, Pages 103-110

  Parker, Christopher C ^a   Dearnaley, David P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Localized prostate cancer; PSA failure; Radical radiotherapy

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN BLOOD LEVEL; ANTIGEN EXPRESSION; CANCER LOCALIZATION; CANCER SURVIVAL; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT FAILURE;

AGED; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 0032416018     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(98)00107-8     Document Type: Review

References (40)

1. Ahlering T.E., Lieskovsky G., Skinner D.G. Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J. Urol. 147:1992;900-902.
2. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1997;37:1035-1041.
3. Bales G.T., Williams M.J., Sinner M., Thisted R.A., Chodak G.W. Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology. 46:1995;676-680.
4. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin (see comments). N. Engl. J. Med. 337:1997;295-300.
5. Carson C.C.D., Zincke H., Utz D.C., Cupps R.E., Farrow G.M. Radical prostatectomy after radiotherapy for prostatic cancer. J. Urol. 124:1980;237-239.
6. Chang S.C., Buonaccorsi G.A., MacRobert A.J., Bown S.G. Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX. Prostate. 32:1997;89-98.
7. Coogan C.L., McKiel C.F. Percutaneous cryoablation of the prostate: preliminary results after 95 procedures. J. Urol. 154:1995;1813-1817.
8. Crook J.M., Bahadur Y.A., Bociek R.G., Perry G.A., Robertson S.J., Esche B.A. Radiotherapy for localized prostate carcinoma: the correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer. 79:1997;328-336.
9. D'Amico A.V., Hanks G.E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer. 72:1993;2638-2643.
10. Dearnaley D.P. Radiotherapy for prostate cancer: the changing scene. Clin. Oncol. 7:1995;147-150.
11. Granfors T., Modig H., Damber J.E., Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J. Urol. 159:1998;2030-2034.
12. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization and future directions. Int. J. Radiat. Oncol. Biol. Phys. 41:1998;501-510.
13. Kahn D., Williams R.D., Haseman M.K., Reed N.L., Miller S.J., Gerbstbrein J. Radioimmunoscintigraphy with in-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostectomy. J. Clin. Oncol. 16:1998;284-289.
14. Kaisary A.V. Antiandrogen monotherapy in the management of advanced prostate cancer. Eur. Urol. 2:1997;14-19.
15. Lee W.R., Hanks G.E., Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J. Clin. Oncol. 15:1997;230-238.
16. Lerner S.E., Blute M.L., Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J. Urol. 154:1995;1103-1109.
17. Link P., Freiha F.S. Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology. 37:1991;189-192.
18. Loening S.A., Turner J.W. Use of percutaneous transperineal 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy. Prostate. 23:1993;283-290.
19. Malcolm A.L., ter Haar G.R. Ablation of tissue volumes using high intensity focused ultrasound. Ultrasound Med. Biol. 22:1996;659-669.
20. Medical Research Council Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br. J. Urol. 1997;79:235-246.
21. Mettlin C. Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer Studies, 1974-1993. Prostate. 32:1997;221-226.
22. Miller R.J. Jr., Cohen J.K., Shuman B., Merlotti L.A. Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma. Cancer. 77:1996;1510-1514.
23. Moul J.W., Paulson D.F. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer. 68:1991;1265-1271.
24. Neerhut G.J., Wheeler T., Cantini M., Scardino P.T. Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J. Urol. 140:1988;544-549.
25. Pisters L.L., von Eschenbach A.C., Scott S.M., et al. The efficacy and complications of salvage cryotherapy of the prostate. J. Urol. 157:1997;921-925.
26. Pollack A., Zagars G.K., Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 74:1994;670-678.
27. Pontes J.E., Montie J., Klein E., Huben R. Salvage surgery for radiation failure in prostate cancer. Cancer. 71:1993;976-980.
28. Prostate Cancer Trialists Collaborative Group. Maximal androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-269.
29. Ritter M.A., Messing E.M., Shanahan T.G., Potts S., Chappell R.J., Kinsella T.J. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol. 10:1992;1208-1217.
30. Rogers E., Ohori M., Kassabian V.S., Wheeler T.M., Scardino P.T. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels (see comments). J. Urol. 153:1995;104-110.
31. Sartor C.I., Strawderman M.H., Lin X.H., Kish K.E., McLaughlin P.W., Sandler H.M. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;941-947.
32. Schellhammer P.F. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer: will more prove better? Int. J. Radiat. Oncol. Biol. Phys. 41:1998;489-490.
33. Stein A., Smith R.B., deKernion T.B. Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate. Urology. 40:1992;197-200.
34. Thompson I.M., Rounder J.B., Spence C.R., Rodriguez F.R. Salvage radical prostatectomy for adenocarcinoma of the prostate. Cancer. 61:1988;1464-1466.
35. Wallner K.E., Nori D., Morse M.J., Sogani P.C., Whitmore W.F., Fuks Z. 125iodine reimplantation for locally progressive prostatic carcinoma. J. Urol. 144:1990;704-706.
36. Wasson JH, Fowler FJ Jr., Barry MJ. Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. J. Urol. 1998;159:1993-1996; discussion 1996-1997.
37. Wasson JH, Fowler FJ Jr., Barry MJ. Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. J. Urol. 1998;159:1993-1996; discussion 1996-1997.
38. Zagars G.K., Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother. Oncol. 44:1997;213-221.
39. Zagars G.K., Pollack A. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer. 72:1993;832-842.
40. Zagars G.K., Pollack A., Von Eschenbach A.C. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 79:1997;1370-1380.